Get the Stockscreener App
22.46
1.36%
-0.31
After Hours:
22.46
Artivion Inc stock is traded at $22.46, with a volume of 651.62K.
It is down -1.36% in the last 24 hours and down -39.35% over the past month.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
See More
Previous Close:
$22.77
Open:
$22.77
24h Volume:
651.62K
Relative Volume:
1.16
Market Cap:
$1.09B
Revenue:
$441.33M
Net Income/Loss:
$9.76M
P/E Ratio:
112.41
EPS:
0.1998
Net Cash Flow:
$839.00K
1W Performance:
-1.36%
1M Performance:
-39.35%
6M Performance:
-50.23%
1Y Performance:
-21.08%
1-Day Range:
$22.17
$23.05
1-Week Range:
$21.76
$24.70
52-Week Range:
$19.16
$48.25
Artivion Inc Stock (AORT) Company Profile
Name
Artivion Inc
Sector
Industry
Phone
(770) 419-3355
Address
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
22.46 | 1.11B | 441.33M | 9.76M | 839.00K | 0.1998 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-13-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-17-25 | Initiated | Canaccord Genuity | Buy |
| Oct-23-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-22 | Reiterated | Lake Street | Buy |
| Aug-08-22 | Initiated | Lake Street | Buy |
| Mar-03-22 | Initiated | Stifel | Buy |
View All
Artivion Inc Stock (AORT) Latest News
Artivion Q1 earnings call highlights - MSN
Artivion secures FDA approval for NEXUS aortic arch system - MSN
Artivion (AORT) Q1 earnings and revenues surpass estimates - MSN
Artivion (AORT) director corrects details of restricted stock award - Stock Titan
Artivion (AORT) director receives 7,576-share equity RSA grant - Stock Titan
Artivion Completes Endospan Acquisition, Expands Aortic Arch Portfolio With FDA-Approved NEXUS System - MedTech Intelligence
Artivion (NYSE:AORT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of - Yahoo Finance
Artivion (AORT) director receives 7,850-share stock award, now holds 56,938 - Stock Titan
Artivion Earnings Call Balances Growth With Caution - TipRanks
Artivion closes Endospan buyout to acquire recently approved heart device - MedTech Dive
Artivion Bets On Full Aortic Arch Suite After Endospan Deal - Yahoo Finance
Artivion strengthens aortic arch portfolio with $135m Endospan acquisition - MSN
Artivion (AORT) Completes Acquisition of Endospan for Aortic Sol - GuruFocus
Artivion Closes $175 Million Acquisition of Endospan - Moomoo
Artivion Completes Acquisition of Endospan, Secures FDA Approval for NEXUS Aortic Arch System - Minichart
Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN
Artivion Closes $175M Deal for Aortic Arch Maker Endospan - Medical Product Outsourcing
Artivion completes $175M acquisition of Endospan - Investing.com UK
Artivion completes $175M acquisition of Endospan By Investing.com - Investing.com South Africa
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System - BioSpace
Artivion Closes Endospan Acquisition Following FDA Approval of NEXUS Aortic System - citybiz
Artivion completes $135 million Endospan acquisition - Investing.com
Artivion completes $135 million Endospan acquisition By Investing.com - Investing.com Australia
Artivion Completes Strategic Acquisition of Endospan Platform - TipRanks
Artivion completes acquisition of Endospan; $131.3M net upfront, up to $200M contingent - TradingView
Endospan acquisition gives Artivion (NYSE: AORT) FDA-approved NEXUS aortic arch system - Stock Titan
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS - Business Wire
Aortic surgery firm Artivion buys Endospan, NEXUS arch stent maker - Stock Titan
Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding - The Motley Fool
Artivion Q1 2026 Earnings: Revenue Matches Estimates, EPS Misses by 35%News and Statistics - IndexBox
5 Insightful Analyst Questions From Artivion’s Q1 Earnings Call - Yahoo Finance
Artivion, Inc. (NYSE:AORT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Artivion shareholders elect directors and approve executive compensation By Investing.com - Investing.com Nigeria
Artivion shareholders elect directors and approve executive compensation - Investing.com
Artivion Shareholders Back Board, Pay and Auditor Choices - TipRanks
Artivion (AORT) shareholders approve directors, executive pay and Ernst & Young for 2026 - Stock Titan
UBS Group AG Has $12.76 Million Position in Artivion, Inc. $AORT - MarketBeat
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 86 Tel - GuruFocus
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 86 Tells Investors - GuruFocus
Artivion (AORT) price target decreased by 16.86% to 43.73 - MSN
Artivion Inc Stock (AORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):